Nothing Special   »   [go: up one dir, main page]

DE68912232D1 - Konjugate zytotoxischer Arzneimittel. - Google Patents

Konjugate zytotoxischer Arzneimittel.

Info

Publication number
DE68912232D1
DE68912232D1 DE89307916T DE68912232T DE68912232D1 DE 68912232 D1 DE68912232 D1 DE 68912232D1 DE 89307916 T DE89307916 T DE 89307916T DE 68912232 T DE68912232 T DE 68912232T DE 68912232 D1 DE68912232 D1 DE 68912232D1
Authority
DE
Germany
Prior art keywords
drug conjugates
cytotoxic drug
cytotoxic
conjugates
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89307916T
Other languages
English (en)
Other versions
DE68912232T2 (de
Inventor
David Arthur Johnson
Bennett Coleman Laguzza
William Leonard Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE68912232D1 publication Critical patent/DE68912232D1/de
Application granted granted Critical
Publication of DE68912232T2 publication Critical patent/DE68912232T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE68912232T 1988-08-08 1989-08-03 Konjugate zytotoxischer Arzneimittel. Expired - Fee Related DE68912232T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/229,941 US5028697A (en) 1988-08-08 1988-08-08 Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers

Publications (2)

Publication Number Publication Date
DE68912232D1 true DE68912232D1 (de) 1994-02-24
DE68912232T2 DE68912232T2 (de) 1994-05-19

Family

ID=22863313

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68912232T Expired - Fee Related DE68912232T2 (de) 1988-08-08 1989-08-03 Konjugate zytotoxischer Arzneimittel.

Country Status (14)

Country Link
US (1) US5028697A (de)
EP (1) EP0354729B1 (de)
JP (1) JPH02256700A (de)
KR (1) KR900002803A (de)
CN (1) CN1040204A (de)
AU (1) AU619328B2 (de)
DE (1) DE68912232T2 (de)
DK (1) DK382889A (de)
HU (1) HU208161B (de)
IL (1) IL91181A0 (de)
MX (1) MX165003B (de)
NZ (1) NZ230199A (de)
PT (1) PT91371B (de)
ZA (1) ZA895909B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5556623A (en) * 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
JPH072895A (ja) * 1993-04-28 1995-01-06 Eli Lilly & Co 抗体−薬物複合体
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
AU2002217980A1 (en) 2000-12-01 2002-06-11 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
JP4414142B2 (ja) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ES2368941T3 (es) * 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PL2360258T3 (pl) * 2005-02-18 2015-03-31 Angiochem Inc Polipeptydy aprotyniny do transportowania związków przez barierę krew-mózg
BRPI0613005A8 (pt) 2005-07-15 2017-12-26 Angiochem Inc uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
NZ568288A (en) 2005-11-28 2012-02-24 Verrow Pharmaceuticals Inc Compositions comprising a a cyclodextrin and a nephrotoxic anticancer drug
EP2126127B1 (de) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
EP2265274B1 (de) 2008-03-03 2018-11-21 Tosk, Inc. Methotrexat-adjuvantien zur verringerung der toxizität und anwendungsverfahren dafür
MX355683B (es) * 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
AU2009322043A1 (en) * 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2747220A1 (en) 2008-12-17 2010-06-24 Richard Beliveau Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
CA2835819A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Induction of immune tolerance using methotrexate
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
AU2014373574B2 (en) 2013-12-27 2020-07-16 Zymeworks Bc Inc. Sulfonamide-containing linkage systems for drug conjugates
KR102609034B1 (ko) 2014-09-17 2023-12-01 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3482444D1 (de) * 1983-03-30 1990-07-19 Lilly Industries Ltd Immunoglobulinkonjugate.
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5030719A (en) * 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US4918165A (en) * 1987-07-16 1990-04-17 Ophthalmic Research Corporation Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction

Also Published As

Publication number Publication date
PT91371B (pt) 1995-05-04
EP0354729A2 (de) 1990-02-14
KR900002803A (ko) 1990-03-23
DE68912232T2 (de) 1994-05-19
JPH02256700A (ja) 1990-10-17
EP0354729B1 (de) 1994-01-12
AU3933889A (en) 1990-02-08
IL91181A0 (en) 1990-03-19
DK382889A (da) 1990-02-09
EP0354729A3 (de) 1991-04-17
ZA895909B (en) 1991-04-24
AU619328B2 (en) 1992-01-23
CN1040204A (zh) 1990-03-07
PT91371A (pt) 1990-03-08
HUT50850A (en) 1990-03-28
DK382889D0 (da) 1989-08-04
US5028697A (en) 1991-07-02
NZ230199A (en) 1991-09-25
HU208161B (en) 1993-08-30
MX165003B (es) 1992-10-13

Similar Documents

Publication Publication Date Title
DE68912232D1 (de) Konjugate zytotoxischer Arzneimittel.
DE69018647D1 (de) Arzneimittel.
ATE131048T1 (de) Arzneimittel.
ATE98480T1 (de) Arzneimittelformulierungen.
DE68901417D1 (de) Pharmazeutische zusammensetzung.
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
ATE163539T1 (de) Arzneimittel
NO912799L (no) Foradditiver for droevtyggere.
AU619329B2 (en) Cytotoxic drug conjugates
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
FI893643A0 (fi) Farmaceutiska kompositioner.
NO892764D0 (no) Medikamentell administreringsform for droevtyggere.
FI905236A0 (fi) Deoxiribonukleosider innehaollande farmaceutiska konsistenser foer laekning av saor.
DE68907392D1 (de) Dysmnesie modifizierende arzneimittel.
DE68915203D1 (de) Pharmazeutische Mischungen.
FI923371A (fi) En farmaceutisk formulation.
EP0299057A4 (de) Verstärkung von zytotoxischen konjugaten.
DE58905160D1 (de) Pharmazeutische zubereitung.
DE68907609D1 (de) Arzneimittelzusammensetzung.
DE69012950D1 (de) Antikrebsmittel.
DE3887237D1 (de) Arzneimittel.
DE68908838D1 (de) Pharmazeutisch wirksame Dithioketen-Derivaten.
ATE100315T1 (de) Arzneimittel.
IT8922215A0 (it) Formulazioni farmaceutiche.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee